Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.

ABSTRACT:

Objectives

Metastatic melanoma patients with leptomeningeal disease (LMD) have an extremely poor prognosis, with a median survival measured in weeks, and few treatment options. Outcomes of a retrospective cohort of patients with LMD that were treated with intrathecal interleukin-2 (IT IL-2) were reviewed to assess the long-term efficacy of this therapy.

Methods

The records of metastatic melanoma patients with LMD who were treated with IT IL-2 from 2006 to 2014 in a Compassionate Investigational New Drug study were reviewed. IL-2 (1.2 mIU) was administered intrathecally via Ommaya reservoir up to five times per week in the inpatient setting for 4 weeks; patients with good tolerance and clinical benefit received maintenance IT IL-2 every 1-3 months thereafter.

Results

T

SUBMITTER: Glitza IC 

PROVIDER: S-EPMC5786950 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature